尿液肾损伤生物标志物的发现和临床应用  

Discovery and clinical application of urinary renal injury biomarkers in kidney disease

作　　者：姚晓甜 杨小兵[1] 侯凡凡[1] Yao Xiaotian;Yang Xiaobing;Hou Fanfan(National Clinical Research Center for Kidney Disease,Nanfang Hospital,Southern Medical University,Guangzhou 510515,Guangdong,China)

机构地区：[1]南方医科大学南方医院国家肾脏病临床医学研究中心,广东广州510515

出　　处：《生物医学转化》2022年第2期9-14,共6页Biomedical transformation

基　　金：国家自然科学基金项目(81970666)。

摘　　要：急性肾损伤(AcuteKidneyInjury,AKI)和慢性肾脏病(ChronicKidneyDisease,CKD)是最常见的肾损伤形式,已成为新的“公共健康问题”。高效识别肾脏高危易损者是目前临床精准监测、精准防治的迫切需要。肾损伤后的信号分子,特别是肾小管上皮细胞损伤后表达的小分子蛋白,能释放至尿液中,尿中水平与肾损伤程度密切相关,是新的肾损伤指标。本文围绕主要的尿液肾损伤生物标志物,介绍它们从基础发现到临床验证,再到临床应用的全过程,最后初步探讨尿液肾损伤标志物研究的未来方向。Acute kidney injury(AKI)and chronic kidney disease(CKD)have become epidemic and public health problems.Discover and validation of novel urinary renal injury biomarkers might help clinicians early recognize high risk individuals who will develop AKI and progressive CKD,thus improve the ability to initiate precise monitoring and timely management of these patients.This paper reviewed recent translational researches in urinary renal injury biomarkers,and summarized the clinical application of novel urinary biomarkers for predicting AKI occurrence and CKD progression.

关 键 词：生物标志物 急性肾损伤 慢性肾脏病 尿液 转化研究 

分 类 号：R692[医药卫生—泌尿科学]